AstragenolCAS# 86541-79-9 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 86541-79-9 | SDF | Download SDF |
PubChem ID | 11944583.0 | Appearance | Powder |
Formula | C30H50O5 | M.Wt | 490.72 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (3S,5R,6S,8S,10S,13R,14S,16S,17R)-17-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-4,4,10,13,14-pentamethyl-2,3,5,6,7,8,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3,6,16-triol | ||
SMILES | CC1(C(CCC2(C1C(CC3C2=CCC4(C3(CC(C4C5(CCC(O5)C(C)(C)O)C)O)C)C)O)C)O)C | ||
Standard InChIKey | KNESISUQBYQIIU-LOIFQKOGSA-N | ||
Standard InChI | InChI=1S/C30H50O5/c1-25(2)21(33)10-12-27(5)17-9-13-28(6)24(30(8)14-11-22(35-30)26(3,4)34)20(32)16-29(28,7)18(17)15-19(31)23(25)27/h9,18-24,31-34H,10-16H2,1-8H3/t18-,19+,20+,21+,22+,23+,24+,27-,28-,29+,30-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Astragenol Dilution Calculator
Astragenol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.0378 mL | 10.1891 mL | 20.3782 mL | 40.7564 mL | 50.9455 mL |
5 mM | 0.4076 mL | 2.0378 mL | 4.0756 mL | 8.1513 mL | 10.1891 mL |
10 mM | 0.2038 mL | 1.0189 mL | 2.0378 mL | 4.0756 mL | 5.0946 mL |
50 mM | 0.0408 mL | 0.2038 mL | 0.4076 mL | 0.8151 mL | 1.0189 mL |
100 mM | 0.0204 mL | 0.1019 mL | 0.2038 mL | 0.4076 mL | 0.5095 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Yuanhuacine
Catalog No.:BCX0743
CAS No.:60195-70-2
- Taxifolin 7-O-β-D-glucoside
Catalog No.:BCX0742
CAS No.:14292-40-1
- Edgeworoside C
Catalog No.:BCX0741
CAS No.:126221-40-7
- Lentinan
Catalog No.:BCX0740
CAS No.:37339-90-5
- 6-Methoxyldihydrochelerythrine
Catalog No.:BCX0739
CAS No.:21080-31-9
- (-)-Myrtenal
Catalog No.:BCX0738
CAS No.:18486-69-6
- Fructo-oligosaccharide DP13/GF12
Catalog No.:BCX0737
CAS No.:137405-37-9
- Fructo-oligosaccharide DP9/GF8
Catalog No.:BCX0736
CAS No.:143625-74-5
- Glucosinalbin
Catalog No.:BCX0735
CAS No.:19253-84-0
- Fructo-oligosaccharide DP10/GF9
Catalog No.:BCX0734
CAS No.:118150-64-4
- (9Z,12Z,15Z)-N-[(3-Methoxyphenyl)methyl]-9,12,15-octadecatrienamide
Catalog No.:BCX0733
CAS No.:883715-23-9
- Fructo-oligosaccharide DP14/GF13
Catalog No.:BCX0732
CAS No.:137405-38-0
- Saikosaponin K
Catalog No.:BCX0745
CAS No.:405229-61-0
- guan-fu base H
Catalog No.:BCX0746
CAS No.:4758-99-0
- Kuwanon B
Catalog No.:BCX0747
CAS No.:62949-78-4
- Yuanhuadine
Catalog No.:BCX0748
CAS No.:76402-66-9
- Emetine
Catalog No.:BCX0749
CAS No.:483-18-1
- Epipinoresinol-4-O-glucopyranoside
Catalog No.:BCX0750
CAS No.:24404-49-7
- Cyaonoside A
Catalog No.:BCX0751
CAS No.:110081-91-9
- Epimedin I
Catalog No.:BCX0752
CAS No.:205445-00-7
- Kuwanon T
Catalog No.:BCX0753
CAS No.:100187-66-4
- luteolin-7-O-gentiobiside
Catalog No.:BCX0754
CAS No.:70855-41-3
- Dihydroferulic acid
Catalog No.:BCX0755
CAS No.:1135-23-5
- Ergothioneine
Catalog No.:BCX0756
CAS No.:497-30-3
Microbial Transformation of Cycloastragenol and Astragenol by Endophytic Fungi Isolated from Astragalus Species.[Pubmed:31713424]
J Nat Prod. 2019 Nov 22;82(11):2979-2985.
Biotransformation of Astragalus sapogenins (cycloAstragenol (1) and Astragenol (2)) by Astragalus species originated endophytic fungi resulted in the production of five new metabolites (3, 7, 10, 12, 14) together with 10 known compounds. The structures of the new compounds were established by NMR spectroscopic and HRMS analysis. Oxygenation, oxidation, epoxidation, dehydrogenation, and ring cleavage reactions were observed on the cycloartane (9,19-cyclolanostane) nucleus. The ability of the compounds to increase telomerase activity in neonatal cells was also evaluated. After prescreening studies to define potent telomerase activators, four compounds were selected for subsequent bioassays. These were performed using very low doses ranging from 0.1 to 30 nM compared to the control cells treated with DMSO. The positive control cycloAstragenol and 8 were found to be the most active compounds, with 5.2- (2 nM) and 5.1- (0.5 nM) fold activations versus DMSO, respectively. At the lowest dose of 0.1 nM, compounds 4 and 13 provided 3.5- and 3.8-fold activations, respectively, while cycloAstragenol showed a limited activation (1.5-fold).
Cycloartane-type sapogenol derivatives inhibit NFkappaB activation as chemopreventive strategy for inflammation-induced prostate carcinogenesis.[Pubmed:29678446]
Steroids. 2018 Jul;135:9-20.
Chronic inflammation is associated to 25% of cancer cases according to epidemiological data. Therefore, inhibition of inflammation-induced carcinogenesis can be an efficient therapeutic approach for cancer chemoprevention in drug development studies. It is also determined that anti-inflammatory drugs reduce cancer incidence. Cell culture-based in vitro screening methods are used as a fast and efficient method to investigate the biological activities of the biomolecules. In addition, saponins are molecules that are isolated from natural sources and are known to have potential for tumor inhibition. Studies on the preparation of analogues of cycloartane-type sapogenols (9,19-cyclolanostanes) have so far been limited. Therefore we have decided to direct our efforts toward the exploration of new anti-tumor agents prepared from cycloAstragenol and its production artifact Astragenol. The semi-synthetic derivatives were prepared mainly by oxidation, condensation, alkylation, acylation, and elimination reactions. After preliminary studies, five sapogenol analogues, two of which were new compounds (2 and 3), were selected and screened for their inhibitory activity on cell viability and NFkappaB signaling pathway activity in LNCaP prostate cancer cells. We found that the Astragenol derivatives 1 and 2 as well as cycloAstragenol derivatives 3, 4, and 5 exhibited strong inhibitory activity on NFkappaB signaling leading the repression of NFkappaB transcriptional activation and suppressed cell proliferation. The results suggested that these molecules might have significant potential for chemoprevention of prostate carcinogenesis induced by inflammatory NFkappaB signaling pathway.
Smith degradation, an efficient method for the preparation of cycloastragenol from astragaloside IV.[Pubmed:24613799]
Fitoterapia. 2014 Jun;95:42-50.
CycloAstragenol (CA) is the genuine sapogenin of astragaloside IV (ASI). This study focuses on the preparation of CA from ASI. Five hydrolysis methods were compared including H2SO4 hydrolysis, HCl hydrolysis, two-phase acid hydrolysis, mild acid hydrolysis, and Smith degradation. Seven hydrolysis products were purified, and five of them were identified as new compounds. The results indicated that Smith degradation was the most effective approach to prepare CA. In contrast, mild acid hydrolysis produced CA at a low yield, accompanied with the artificial sapogenin Astragenol. The other three acid hydrolysis methods mainly produced Astragenol. Furthermore, the reaction conditions for Smith degradation were optimized as follows: ASI was dissolved in 60% MeOH-H2O solution, oxidized with 5 equiv. NaIO4 for 12h, followed by reduction with 3 equiv. NaBH4 for 4h, and finally acidified with 1M H2SO4 at pH2 for 24h. Under the optimal conditions, CA could be prepared from ASI at a yield of 84.4%.